UroAlert - GU Oncology Daily

November 28, 2024

Videos

Peer-to-Peer Clinical Conversations

Quality of life after Trimodality Therapy - Kimberley Mak

Kimberley Mak

Leslie Ballas speaks with Kimberley about quality of life considerations for bladder cancer patients undergoing trimodality therapy (TMT), following discussions at the Bladder Cancer Advocacy Network Think Tank.

MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter

Phuoc Tran

Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer.

Beyond the Abstracts

Impact of TP53 Loss-of-Function Alterations on the Response to PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract

Conference Coverage

ESMO 2024: Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: Conditional Survival and Long-Term Safety in Patients Treated for ≥1 or ≥2 Years in JAVELIN Bladder 100

ESMO 2024: Invited Discussant: A Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA)

ESMO 2024: Invited Discussant: Futibatinib Plus Pembrolizumab, Retrospective Assessment of Nectin-4 Expression, and Disitamab Vedotin

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract

Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.

Renal Cancer

Calcium Channel Blocker Versus Renin-Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score-Matched Cohort Study.

Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma.

Prostate Cancer

Impact of TP53 Loss-of-Function Alterations on the Response to PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract

Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer.

Cross-shaped windows transformer with self-supervised pretraining for clinically significant prostate cancer detection in bi-parametric MRI.

Nutritional Supplement with Fermented Soy in Patients Under Active Surveillance for Low-Risk or Intermediate-Risk Prostate Cancer: Results from the PRAEMUNE Trial.

Phenotypic evaluation of deep learning models for classifying germline variant pathogenicity.

Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.

Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer.

Upper Tract Tumors

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) with UGN-101, A Mitomycin Reverse Thermal Gel

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC